This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Rosny, E.
Right arrow Articles by Weiss, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Rosny, E.
Right arrow Articles by Weiss, C. D.

 Previous Article  |  Next Article 

Journal of Virology, September 2001, p. 8859-8863, Vol. 75, No. 18
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.18.8859-8863.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Peptides Corresponding to the Heptad Repeat Motifs in the Transmembrane Protein (gp41) of Human Immunodeficiency Virus Type 1 Elicit Antibodies to Receptor-Activated Conformations of the Envelope Glycoprotein

Eve de Rosny,1 Russell Vassell,1 Paul T. Wingfield,2 Carl T. Wild,3 and Carol D. Weiss1,*

Office of Vaccines, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA),1 and Protein Expression Laboratory, National Institute of Arthritis and Musculosketal and Skin Diseases, National Institutes of Health,2 Bethesda, and Panacos Pharmaceuticals, Gaithersburg,3 Maryland

Received 23 March 2001/Accepted 18 June 2001

Two heptad repeat regions in the ectodomain of the human immunodeficiency virus type 1 (HIV-1) transmembrane subunit (gp41) self-assemble into a six-helix bundle structure that is critical for virus entry. Immunizations with peptides corresponding to these regions generated antibodies specific to the receptor-activated conformations of gp41.

* Corresponding author. Mailing address: FDA/CBER, HFM-466, NIH Bldg. 29, Room 532, 29 Lincoln Dr., Bethesda, MD 20892-4555. Phone: (301) 402-3190. Fax: (301) 496-4684. E-mail: cdweiss{at}helix.nih.gov.

Journal of Virology, September 2001, p. 8859-8863, Vol. 75, No. 18
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.18.8859-8863.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Wang, H., Qi, Z., Guo, A., Mao, Q., Lu, H., An, X., Xia, C., Li, X., Debnath, A. K., Wu, S., Liu, S., Jiang, S. (2009). ADS-J1 Inhibits Human Immunodeficiency Virus Type 1 Entry by Interacting with the gp41 Pocket Region and Blocking Fusion-Active gp41 Core Formation. Antimicrob. Agents Chemother. 53: 4987-4998 [Abstract] [Full Text]  
  • Mirsaliotis, A., Nurkiyanova, K., Lamb, D., Kuo, C.-W. S., Brighty, D. W. (2007). Resistance to Neutralization by Antibodies Targeting the Coiled Coil of Fusion-active Envelope Is a Common Feature of Retroviruses. J. Biol. Chem. 282: 36724-36735 [Abstract] [Full Text]  
  • Perez-Romero, P., Fuller, A. O. (2005). The C Terminus of the B5 Receptor for Herpes Simplex Virus Contains a Functional Region Important for Infection. J. Virol. 79: 7431-7437 [Abstract] [Full Text]  
  • Lenz, O., Dittmar, M. T., Wagner, A., Ferko, B., Vorauer-Uhl, K., Stiegler, G., Weissenhorn, W. (2005). Trimeric Membrane-anchored gp41 Inhibits HIV Membrane Fusion. J. Biol. Chem. 280: 4095-4101 [Abstract] [Full Text]  
  • Greenberg, M. L., Cammack, N. (2004). Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 54: 333-340 [Abstract] [Full Text]  
  • de Rosny, E., Vassell, R., Jiang, S., Kunert, R., Weiss, C. D. (2004). Binding of the 2F5 Monoclonal Antibody to Native and Fusion-Intermediate Forms of Human Immunodeficiency Virus Type 1 gp41: Implications for Fusion-Inducing Conformational Changes. J. Virol. 78: 2627-2631 [Abstract] [Full Text]  
  • Markovic, I., Stantchev, T. S., Fields, K. H., Tiffany, L. J., Tomic, M., Weiss, C. D., Broder, C. C., Strebel, K., Clouse, K. A. (2004). Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry. Blood 103: 1586-1594 [Abstract] [Full Text]  
  • Murakami, T., Ablan, S., Freed, E. O., Tanaka, Y. (2004). Regulation of Human Immunodeficiency Virus Type 1 Env-Mediated Membrane Fusion by Viral Protease Activity. J. Virol. 78: 1026-1031 [Abstract] [Full Text]  
  • Sia, S. K., Kim, P. S. (2003). Protein grafting of an HIV-1-inhibiting epitope. Proc. Natl. Acad. Sci. USA 100: 9756-9761 [Abstract] [Full Text]  
  • Song, C., Hunter, E. (2003). Variable Sensitivity to Substitutions in the N-Terminal Heptad Repeat of Mason-Pfizer Monkey Virus Transmembrane Protein. J. Virol. 77: 7779-7785 [Abstract] [Full Text]  
  • Kilgore, N. R., Salzwedel, K., Reddick, M., Allaway, G. P., Wild, C. T. (2003). Direct Evidence that C-Peptide Inhibitors of Human Immunodeficiency Virus Type 1 Entry Bind to the gp41 N-Helical Domain in Receptor-Activated Viral Envelope. J. Virol. 77: 7669-7672 [Abstract] [Full Text]  
  • Louis, J. M., Nesheiwat, I., Chang, L., Clore, G. M., Bewley, C. A. (2003). Covalent Trimers of the Internal N-terminal Trimeric Coiled-coil of gp41 and Antibodies Directed against Them Are Potent Inhibitors of HIV Envelope-mediated Cell Fusion. J. Biol. Chem. 278: 20278-20285 [Abstract] [Full Text]  
  • Binley, J. M., Cayanan, C. S., Wiley, C., Schulke, N., Olson, W. C., Burton, D. R. (2003). Redox-Triggered Infection by Disulfide-Shackled Human Immunodeficiency Virus Type 1 Pseudovirions. J. Virol. 77: 5678-5684 [Abstract] [Full Text]  
  • Markosyan, R. M., Cohen, F. S., Melikyan, G. B. (2003). HIV-1 Envelope Proteins Complete Their Folding into Six-helix Bundles Immediately after Fusion Pore Formation. Mol. Biol. Cell 14: 926-938 [Abstract] [Full Text]  
  • He, Y., Vassell, R., Zaitseva, M., Nguyen, N., Yang, Z., Weng, Y., Weiss, C. D. (2003). Peptides Trap the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Fusion Intermediate at Two Sites. J. Virol. 77: 1666-1671 [Abstract] [Full Text]  
  • Finnegan, C. M., Berg, W., Lewis, G. K., DeVico, A. L. (2002). Antigenic Properties of the Human Immunodeficiency Virus Transmembrane Glycoprotein during Cell-Cell Fusion. J. Virol. 76: 12123-12134 [Abstract] [Full Text]  
  • Giannecchini, S., Isola, P., Sichi, O., Matteucci, D., Pistello, M., Zaccaro, L., Del Mauro, D., Bendinelli, M. (2002). AIDS Vaccination Studies Using an Ex Vivo Feline Immunodeficiency Virus Model: Failure To Protect and Possible Enhancement of Challenge Infection by Four Cell-Based Vaccines Prepared with Autologous Lymphoblasts. J. Virol. 76: 6882-6892 [Abstract] [Full Text]  
  • Golding, H., Zaitseva, M., de Rosny, E., King, L. R., Manischewitz, J., Sidorov, I., Gorny, M. K., Zolla-Pazner, S., Dimitrov, D. S., Weiss, C. D. (2002). Dissection of Human Immunodeficiency Virus Type 1 Entry with Neutralizing Antibodies to gp41 Fusion Intermediates. J. Virol. 76: 6780-6790 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»